logo
Cutting Food Stamps Isn't Just Cruel, It's Also Bad Economic Policy

Cutting Food Stamps Isn't Just Cruel, It's Also Bad Economic Policy

Eater22-05-2025

Well into the wee hours of Thursday morning, House Republicans were hard at work doing what they do best: making the lives of all but the wealthiest Americans harder. After hours of debate, the Republican-led House narrowly passed the 'Big Beautiful Bill' championed by Donald Trump, which brings hundreds of billions of dollars in funding cuts to essential programs like Medicaid and the Supplemental Nutrition Assistance Program (SNAP), better known as food stamps.
These $300 billion in proposed cuts will have devastating consequences for low-income Americans, many of whom are already struggling because everything, from rent to groceries, has gotten exponentially more expensive in recent years. In addition to nearly $300 million in SNAP budget cuts, the legislation would also increase work requirements for those receiving benefits for longer than three months, and shift a portion of the financial responsibility for SNAP to state budgets. According to CNN, that shift could result in some states limiting enrollment in assistance programs, or pulling out of SNAP altogether. Currently, it's estimated that around 11 million people, including 4 million children, would lose access to SNAP benefits.
But despite the touted federal government 'savings,' these cuts to Medicaid and SNAP will have a devastating impact on the economy. There is pretty solid consensus among economists and other policy experts that programs like SNAP have obvious — and immediate — economic benefits. When the economy is bad, SNAP dollars are immediately infused back into the system, resulting in $1.50 in GDP growth for every $1 spent. SNAP spending also creates jobs, lowers healthcare costs, improves academic outcomes for children, and generally reduces poverty.
Conversely, every time there are cuts to SNAP, the economy suffers: Farmers and grocers lose money, supermarket workers get laid off, and state and local budgets get strapped as local officials try to meet the demand for food assistance. If the cuts that just passed the House become law, projections indicate they could be catastrophic: one estimate suggests 1 million jobs will be lost, and states will see $113 billion in GDP losses. According to Sen. Amy Klobuchar, chair of the Senate Committee on Agriculture, Nutrition, and Forestry, farmers will see billions in lost revenue, and workers in industries from trucking to supermarkets will lose their jobs. The president of Indiana's Gleaners Food Bank described the impact of the proposed cuts as a 'needless, self-inflicted humanitarian and economic disaster for Indiana and the country.'
The SNAP program is the definition of a policy-no-brainer, and yet it remains controversial among conservative politicians because the thought of someone — even a child or elderly person! — obtaining something that they did not pay for is just untenable to the worst people among us. (Corporate welfare is, apparently, totally cool though.) I don't know how we fix that idea, that people in the richest country in the world are 'entitled' or 'greedy' for simply wanting enough food to eat, but you would think that this cruelty might be somewhat mitigated by the Republican party's own economic self-interest — and the interest of their wealthy constituents, but alas. It is clear that for House Speaker Mike Johnson and Trump, a little short-term political boost that doubles as a sucker-punch to poor Americans is worth the long-term economic pinch that will inevitably come as a result of these cuts.
This legislation is, thankfully, not yet law. It's headed back to the Senate, and it's unclear which parts of the bill will survive, though Trump and the GOP seem determined to decimate SNAP and Medicaid. What is abundantly clear, though, is that it's time to stop viewing the fight over food stamps as having anything to do with making the economy better. It is, explicitly, a fight over who deserves to eat, and Trump and his cronies have made brutally clear which side they're on.
The freshest news from the food world every day

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'

Newsweek

time9 minutes ago

  • Newsweek

Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.

Analysts assess the potential impact of Trump's surprise 50% steel tariffs
Analysts assess the potential impact of Trump's surprise 50% steel tariffs

Yahoo

time13 minutes ago

  • Yahoo

Analysts assess the potential impact of Trump's surprise 50% steel tariffs

-- U.S. President Donald Trump unexpectedly announced on Friday that steel and aluminum tariffs will double to 50%. The move, set to come into effect on June 4, was unveiled during a campaign rally in Pennsylvania. It was later confirmed on TruthSocial and comes amid broader debates around U.S. industrial policy and foreign investment. Analysts are now evaluating the implications of this surprise decision, with most agreeing that the immediate domestic effects may be less severe than the broader geopolitical risks. JPMorgan's Tatsuya Maruyama said the direct impact on major Japanese steelmakers such as Nippon Steel Corp (TYO:5401), JFE Holdings, Inc. (TYO:5411), and Kobe Steel, Ltd. (TYO:5406) is expected to be limited, given that 'the U.S. accounts for about 4% of Japan's steel exports.' Maruyama pointed out in a Monday note that Nippon Steel and JFE export only about 1% of their total shipments to the U.S., while Kobe Steel exports about 3%. Still, he warned that 'rising global protectionism' is a growing concern, noting that a wave of anti-dumping measures and safeguards in regions like South Korea, the EU, and India could further strain global trade dynamics. 'If such countermeasures gain momentum, Japanese steel products may also be targeted and the export environment may worsen,' Maruyama continued. Meanwhile, analysts at BMO Capital Markets believe the sudden tariff hike could jolt domestic markets. 'The doubling of import tariffs, if maintained, is likely to create a panic in the market and trigger a restocking cycle that in our view has the potential to push prices >$1,000/st in the near-term,' the analysts said. However, they believe the spike would be temporary given macro uncertainty and seasonal demand trends. The broker upgraded Nucor (NYSE:NUE) to Outperform but downgraded Algoma Central (TSX:ALC), which it called 'a relative tariff loser.' The aluminum market may be more exposed, according to BMO. The U.S. covers only about 20% of its own aluminum consumption domestically, making it more vulnerable to supply disruptions. 'If tariffs do double, this is expected to put material upside pressure on the Midwest premium (MWP),' BMO wrote, estimating it could reach '$0.75/lb-plus' in theory, although higher aluminum cost will likely weigh on demand and thus offset some upside pressure. That said, the brokerage sees Century Aluminum (NASDAQ:CENX) as well positioned to benefit from a rise in the Midwest premium, while Alcoa (NYSE:AA) could see a negative impact of $1–2 per share, or 4–7%, due to its reliance on Canadian production. Still, BMO expects Alcoa may redirect some of its Canadian output to the EU market. Related articles Analysts assess the potential impact of Trump's surprise 50% steel tariffs Street Calls of the Week VIDEO: How to analyze a stock like a pro with the CEO of HF Foods

1 Value Stock on Our Buy List and 2 to Approach with Caution
1 Value Stock on Our Buy List and 2 to Approach with Caution

Yahoo

time13 minutes ago

  • Yahoo

1 Value Stock on Our Buy List and 2 to Approach with Caution

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues. Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored. Forward P/E Ratio: 14.5x Synonymous with "dad shoe", Skechers (NYSE:SKX) is a footwear company renowned for its comfortable, stylish, and affordable shoes for all ages. Why Is SKX Risky? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Estimated sales growth of 7.4% for the next 12 months implies demand will slow from its two-year trend Poor free cash flow margin of 4.4% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends Skechers is trading at $62.04 per share, or 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than SKX. Forward P/E Ratio: 9.9x Established in 1878, Mohawk Industries (NYSE:MHK) is a leading producer of floor-covering products for both residential and commercial applications. Why Are We Out on MHK? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth ROIC of 3.5% reflects management's challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned At $100.61 per share, Mohawk Industries trades at 9.9x forward P/E. Check out our free in-depth research report to learn more about why MHK doesn't pass our bar. Forward P/E Ratio: 3.7x Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Are We Bullish on SRPT? Annual revenue growth of 51.3% over the last two years was superb and indicates its market share increased during this cycle Earnings per share grew by 38.8% annually over the last five years, massively outpacing its peers Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business Sarepta Therapeutics's stock price of $37.50 implies a valuation ratio of 3.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store